Lantheus Holdings
By therapeutic area
| Therapeutic area | Premium | Deals |
|---|---|---|
| oncology | ×1.50 | 3 |
By stage at signing
Not enough phase-specific data (need ≥3 deals per phase).
Strategy profile
Based on 9 disclosed transactions, Lantheus Holdings concentrates its licensing activity in Oncology. Lantheus Holdings pays a 1.50x premium over market median, with the strongest premiums in Oncology (1.50x). Their most common deal structure is License, with an average disclosed value of $1.0B. Most recent activity: 2025.
Premium by therapeutic area
How Lantheus Holdings pays relative to peer medians in each TA
Pipeline coverage & gaps
Lantheus Holdings has disclosed activity in 1 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| LicensePrimary | 5 | $154M | $1.1B |
| Acquisition | 4 | $275M | $939M |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2025 | OCTEVY | Evergreen Theragnostics | oncology diagnostic imaging | phase_3 | $250M | $1.0B |
| 2025 | Evergreen Theragnostics (radioligand platform) | Evergreen Theragnostics | thyroid cancer | unknown | $250M | $1.0B |
| 2025 | PET diagnostic agent for neuroendocrine tumors | Evergreen Theragnostics | neuroendocrine tumors | unknown | $250M | $1.0B |
| 2025 | Life Molecular Imaging (full company acquisition) | Life Molecular Imaging | neuroendocrine tumors | approved | $350M | $750M |
| 2024 | neuroendocrine | Radiopharm Theranostics | neuroendocrine | phase_2 | $250M | $1.2B |
| 2022 | PNT2003 | POINT Biopharma | prostate cancer | preclinical | $10M | $315M |
| 2022 | PNT2002 | POINT Biopharma | mCRPC (metastatic castration-resistant prostate cancer) | phase_2 | $250M | $1.8B |
| 2022 | PNT2003 | POINT Biopharma | gastroenteropancreatic neuroendocrine tumors (GEP-NETs) | phase_3 | $10M | $315M |
| 2022 | PNT2002 | POINT Biopharma | metastatic castration-resistant prostate cancer (mCRPC) | phase_3 | $250M | $1.8B |
How this is computed
For each Lantheus Holdings deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 3 disclosed deal premiums vs. peer medians. Raw premium 2.163, clamped to [0.7, 1.5].